Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

1-41-66 (USA)

The conference call (Call ID 204, followed by the #) will be available for play-back for 48 hours after the call by dialling:
+41-(0)91-612-43-30 (Europe)

+44-(0)207-108-62-33 (UK)

+1-(1)866-416-25-58 (USA)

About Arpida Ltd. Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed four Phase I trials. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...TOCKHOLM, November 20 Karolinska D...vestment Fund (EIF) has entered into a,co-investme...und will be,managed by Karolinska Development and ...-stage pharmaceutical and medical technology compa... co-investment fund. The agreement,represents EIF,...
(Date:11/19/2009)..., Nov. 19 Danish Prince Joachim in...thanol plant in Kalundborg, Denmark, on Wednesday,...irst and largest 2nd generation ethanol demonstrat...are used in the plant,s innovative process for con...isco, was the first to market with commercial enzy...
(Date:11/19/2009)... Md., Nov. 19 Spherix In...chnology for diabetes therapy, and a provider of t...d, supplement, biotechnology and pharmaceutical co...Annual Meeting of Shareholders. ,, At the meeti... SPEX ) elected the following members to the Board...
(Date:11/19/2009)... World,s Top Gene Synthesis Companies Form In...ordinate Best Practices in Risk Reduction ,Five ... Gene Synthesis Capacity , ...squo;s leading gene synthesis companies today anno...ening protocol to promote biosecurity in the gene ...
Breaking Biology Technology:Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 2Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation 3DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...t time in the team,s history, the University of W...d first in the nation, giving Wisconsin fans just ... around the corner, and I know the team will enjoy...,But our support for the entire University of Wis...A tournament. The UW system is a vital institution...
... the technology associated with his digital produc...o address its flaws and transform it for the voice...y-stage Madison business called VoVison , has amb...n technology, which has three differentiating feat...the ability to work with multiple voices. , ,The t...
...e had the chance to play a bit more with the indep...d at the conference, Jaman.com offers a growing li... that average about $6 per film. , ,While you can ...n.com experience is the downloadable player, a des...rpose-built browser . The player manages download...
Other Biology Technology:Fueling our economy with the University of Wisconsin 2Fueling our economy with the University of Wisconsin 3Fueling our economy with the University of Wisconsin 4Tech upstart VoVision could disrupt the voice-recognition market 2Tech upstart VoVision could disrupt the voice-recognition market 3Tech upstart VoVision could disrupt the voice-recognition market 4We're "Jaman": Purpose-driven browsers drive next wave of Web applications 2We're "Jaman": Purpose-driven browsers drive next wave of Web applications 3
(Date:11/19/2009)...ire-FirstCall/ -- BIO-key International, Inc. (OTC...c safety and finger-based biometric identification... Meeting held today was adjourned without any acti..., (Logo: http://www.newscom.com/cgi-bin/prnh/2...% of the 35 million votes cast voted in favor of t...
(Date:11/19/2009)... T. Ming Chu Professor of Biochemistry and Molecul...ng how regulatory proteins control the production ...rking with collaborators including Drs. Mitchell W...ladelphia, they focused specifically on the comple...es). These cells contain large amounts of hemoglob...
(Date:11/19/2009)...professor of paleontology in the McMicken College ... the University of Chicago publish their research ..., "Epicontinental Seas Versus Open-Ocean Settings:... , For many years, paleobiological researchers i...sed on charting the many ups (evolutionary radiati...
Breaking Biology News(10 mins):BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 2Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 3Paleontologists find extinction rates higher in open-ocean settings during mass extinctions 4Where surgery was the standard casting may be the future 58548 1Where surgery was the standard casting may be the future 58548 2Amid rising concerns 600 global biodiversity experts meet in Cape Town Oct 13 16 10185 1Study Finds Fish Wont Prevent Heart Failure 58544 1Study Finds Fish Wont Prevent Heart Failure 58544 2Study Finds Fish Wont Prevent Heart Failure 58544 3
...n genes on and off now looks to be more like a cel...ancer Institute at the University of Utah, report ... , The scientists showed for the first time that ...ied ?flexible, randomly structured regions believe...hey become important in turning genes on and off, ...
... Medical School have discovered the biological equ... of primitive, blood-forming stem cells in mice. C...all the different types of specialized cells found...an separate stem cells from their more advanced de...tted to becoming one type of blood cell. The secre...
...apies were introduced for neglected diseases, whic...of the equivalent of 92m years, of healthy life, t...ay. , In the PLoS Medicine analysis, which is base...Trust, Mary Moran of the London School of Economic...ts are conducted under the umbrella of drug develo...
Other Biology News:A 'dimmer switch' for genes 2A 'dimmer switch' for genes 3U-M scientists discover identifying markers for primitive blood-forming stem cells 2U-M scientists discover identifying markers for primitive blood-forming stem cells 3U-M scientists discover identifying markers for primitive blood-forming stem cells 4
...us venom Description: Phosphodiesterase I (venom e...d structure and sequence (1) . It hydrolyzes 5'-mo...onucleotides and deoxyribo-oligonucleotides (2) . ...ns at the pyrophosphate linkages to yield phosphor...
Spacer for Miniature FRENCH Pressure Cell from Thermo Scientific
...criptase is a recombinant Moloney murine leukemia ... Reverse Transcriptase is similar to MuLV reverse .... MuLV reverse transcriptase is a recombinant RNA-... RNA as a template in the presence of a primer to ...
...to Prostaglandin F2α (8-iso-13,14-dihydro-1...stane, 8-isoprostane (8-iso PGF2α), in rabb...G-like product of non-specific lipid peroxidation....-isoprostane is converted primarily to metabolites...
Biology Products: